



ULTRASOUND-DEFINED ADENOMYOSIS PHENOTYPES AND THEIR ASSOCIATION WITH DYSMENORRHEA SEVERITY AND HEAVY MENSTRUAL BLEEDING

Priya Gupta¹, Indu Rani¹, Shashank Kumar Gupta², Sawarkar Yuganti³

ABSTRACT

Background: Adenomyosis is a common benign uterine disorder associated with dysmenorrhea and heavy menstrual bleeding (HMB). Ultrasound-based phenotyping may help identify morphological patterns associated with greater symptom burden.

Objective: To evaluate the association between ultrasound-defined adenomyosis phenotypes, dysmenorrhea severity, and HMB.

Methods: This retrospective observational study included 270 women aged 16–45 years evaluated at NAMO Medical Education and Research Institute, Silvassa. Adenomyosis was characterized using the revised Morphological Uterus Sonographic Assessment (MUSA) criteria. Dysmenorrhea severity and HMB were assessed from available clinical records, including documented pain scores and menstrual bleeding characteristics.

Results: In the illustrative dataset, dysmenorrhea was present in 72.6% and HMB in 55.9% of patients. Diffuse adenomyosis showed higher frequencies of severe dysmenorrhea (28.9% vs. 14.4%) and HMB (62.7% vs. 45.2%) compared with focal disease. Direct sonographic features showed prominent associations with dysmenorrhea, whereas globular uterus, asymmetrical myometrial thickening, and junctional-zone abnormalities showed stronger patterns with HMB.

Conclusion: Ultrasound-defined adenomyosis phenotypes may demonstrate distinct relationships with menstrual symptoms. Standardized MUSA-based phenotyping could improve clinical characterization and support more individualized assessment of women with adenomyosis.

KEYWORDS: Adenomyosis, Dysmenorrhea, Heavy Menstrual Bleeding, Ultrasonography, MUSA Criteria, Adenomyosis Phenotype

1. INTRODUCTION

Adenomyosis is a benign uterine disorder characterized by the presence of endometrial glands and stroma within the myometrium, often accompanied by myometrial hypertrophy and fibrosis. It is increasingly recognized as an important cause of dysmenorrhea, heavy menstrual bleeding (HMB), chronic pelvic pain, and impaired quality of life among women of reproductive age. However, the clinical presentation is heterogeneous, and

symptom severity may vary considerably among affected women.

Advances in transvaginal ultrasonography (TVUS) have enabled non-invasive diagnosis and characterization of adenomyosis. The revised Morphological Uterus Sonographic Assessment (MUSA) criteria classify sonographic findings into direct features such as myometrial cysts, hyperechogenic islands, and subendometrial lines or buds and indirect

¹ MS Resident,
Obstetrics &
Gynaecology NAMO
MERI,
² MS Resident,
Department of
Ophthalmology,
NAMO MERI,
³ Assistant Professor,
Obstetrics &
Gynaecology, NAMO
MERI

How to Cite:

Priya Gupta, Indu
Rani, Shashank
Kumar Gupta &
Sawarkar Yuganti
(2026), Ultrasound-
Defined Adenomyosis
Phenotypes and
Their Association
with Dysmenorrhea
Severity and Heavy
Menstrual Bleeding,
International
Educational Applied
Scientific & Research
Journal (IEASRJ),
Vol: 11, Issue: 9,
101-105

features, including globular uterus, asymmetrical myometrial thickening, fan-shaped shadowing, translesional vascularity, and irregular or interrupted junctional zone. This standardized approach allows adenomyosis to be evaluated not merely as present or absent but according to its morphological characteristics and disease burden.

Recent evidence suggests that specific ultrasound features may be associated with different clinical manifestations. Junctional-zone abnormalities, globular uterine morphology, and asymmetrical myometrial thickening have been associated with HMB, while direct myometrial features may be related to dysmenorrhea and pelvic pain. Nevertheless, the relationship between ultrasound-defined adenomyosis phenotypes and the severity of menstrual symptoms remains incompletely understood, and available studies show considerable heterogeneity in imaging classification and symptom assessment.

Therefore, the present study aims to evaluate the association of ultrasound-defined adenomyosis phenotypes with dysmenorrhea severity and heavy menstrual bleeding, using standardized sonographic criteria. Identifying phenotype–symptom relationships may improve clinical characterization, patient counselling, and individualized management of women with adenomyosis.

2. MATERIALS AND METHODS

2.1 Study Design and Setting

This retrospective observational study was conducted at NAMO Medical Education and Research Institute (NAMO MERI), Silvassa, Dadra and Nagar Haveli and Daman and Diu, India. Medical records and pelvic ultrasound findings of 270 patients aged 16–45 years who were evaluated for suspected or ultrasound-diagnosed adenomyosis during the predefined study period were reviewed.

2.2 Study Population

A total of 270 patients fulfilling the eligibility criteria were included. Demographic, clinical, menstrual, and ultrasonographic information was retrieved from available hospital records, outpatient records, ultrasound reports, and electronic medical records.

2.3 Inclusion Criteria

Patients were eligible if they:

- were aged 16–45 years;
- underwent pelvic/transvaginal ultrasonography during the study period;
- had ultrasound findings consistent with adenomyosis;
- had adequate ultrasound records for assessment of adenomyosis characteristics; and
- had available information regarding menstrual symptoms, particularly dysmenorrhea and/or menstrual bleeding.

2.4 Exclusion Criteria

Patients were excluded in cases of pregnancy, postmenopausal status, inadequate ultrasound documentation, incomplete clinical records regarding the primary outcomes, known gynecological malignancy, or previous hysterectomy. Coexisting leiomyoma and endometriosis should preferably be recorded rather than automatically excluded, as these conditions may act as important confounders in the relationship between adenomyosis and menstrual symptoms.

2.5 Ultrasound Assessment of Adenomyosis

Ultrasound findings were reviewed according to the revised Morphological Uterus Sonographic Assessment (MUSA) criteria. The revised MUSA consensus separates adenomyosis findings into direct and indirect sonographic features.

Direct features included myometrial cysts, hyperechogenic islands, and echogenic subendometrial lines or buds. Indirect features included globular uterus, asymmetrical myometrial thickening, fan-shaped shadowing, translesional vascularity, irregular junctional zone, and interrupted junctional zone.

Where adequately documented, adenomyosis was further characterized according to its morphological distribution, such as focal or diffuse disease, and according to the number and combination of MUSA features present.

2.6 Assessment of Dysmenorrhea

Dysmenorrhea severity was assessed from documented clinical records. Where a Visual

Analogue Scale (VAS) or Numeric Rating Scale (NRS) was available, pain intensity was recorded on a 0–10 scale, with 0 indicating no pain and 10 indicating the worst pain experienced.

For analysis, dysmenorrhea may be categorized as: 0 = no pain; 1–3 = mild; 4–6 = moderate; and 7–10 = severe dysmenorrhea.

The continuous 0–10 score should additionally be retained for statistical analysis whenever available, rather than relying solely on categories. VAS/NRS-based assessment has been used in recent adenomyosis phenotype–symptom research.

For patients without a documented numerical pain score, dysmenorrhea severity should only be categorized retrospectively when the clinical documentation provides sufficient information to support such classification. Patients with insufficient information should be recorded as having missing pain-severity data rather than being assigned an assumed score.

2.7 Assessment of Heavy Menstrual Bleeding

Heavy menstrual bleeding was assessed from menstrual history documented in the medical records. Where available, menstrual blood loss was quantified using the Pictorial Blood Loss Assessment Chart (PBAC), which assigns scores according to the number and degree of saturation of sanitary products and episodes of clot passage or flooding.

A PBAC score >100 may be used as the operational threshold for HMB when PBAC data are available; this threshold continues to be used in clinical HMB studies.

Because of the retrospective design, patients without a pre-existing PBAC score should not be assigned a fabricated PBAC score. Instead, HMB should be identified from documented clinical descriptions of excessive menstrual bleeding, such as physician-recorded HMB/menorrhagia, frequent sanitary-product changes, flooding, passage of large clots, prolonged excessive bleeding, or other clearly documented evidence of excessive menstrual loss.

Thus, HMB can be analyzed primarily as a binary

variable (present/absent) in patients without PBAC data, while actual PBAC scores can be analyzed quantitatively in the subgroup for whom they are available.

2.8 Data Collection

The following variables were extracted wherever available: age, parity, body mass index (BMI), menstrual-cycle characteristics, dysmenorrhea severity, HMB, hemoglobin level, ultrasound-defined adenomyosis phenotype, individual MUSA features, uterine dimensions/volume, presence of leiomyoma, endometriosis, ovarian pathology, and current hormonal treatment.

Potential confounding factors, particularly age, parity, BMI, leiomyoma, endometriosis, and hormonal treatment, were recorded for adjusted analyses.

2.9 Outcome Measures

The primary outcome was the association between ultrasound-defined adenomyosis phenotype and dysmenorrhea severity.

The secondary outcome was the association between ultrasound-defined adenomyosis phenotype and heavy menstrual bleeding.

Additional analyses evaluated associations between individual MUSA features, total sonographic feature burden, dysmenorrhea severity, and HMB.

2.10 Ethical Considerations

The study protocol should be submitted to/approved by the Institutional Ethics Committee of NAMO Medical Education and Research Institute, Silvassa. As this is a retrospective medical-record review, the requirement for individual informed consent may be waived by the Ethics Committee, subject to institutional policy. Patient confidentiality and anonymity should be maintained throughout data collection and analysis.

3. RESULTS

A total of 270 women aged 16–45 years were included in the illustrative analysis. The mean age was 32.6 ± 7.4 years. The following numerical results are simulated placeholders for manuscript development and do not represent actual patient observations.

Dysmenorrhea was present in 196 (72.6%) patients; 54 (20.0%) had mild, 79 (29.3%) moderate, and 63 (23.3%) severe dysmenorrhea. HMB was recorded in 151 (55.9%) patients.

3.1 Ultrasound Phenotypes and Symptoms

Diffuse adenomyosis was represented in the simulated dataset in 166 (61.5%) patients and focal adenomyosis in 104 (38.5%). Severe dysmenorrhea was more frequent in the diffuse phenotype than in the focal phenotype (28.9% vs. 14.4%, illustrative $p=0.006$). HMB was also more frequent in diffuse adenomyosis (62.7% vs. 45.2%, illustrative $p=0.005$).

3.2 Association of MUSA Features With Symptoms

Ultrasound feature	n (%)	Dysmenorrhea n (%)	HMB n (%)
Myometrial cysts	158 (58.5)	126 (79.7)	94 (59.5)
Hyperechogenic islands	132 (48.9)	103 (78.0)	76 (57.6)
Globular uterus	149 (55.2)	115 (77.2)	101 (67.8)
Asymmetrical thickening	143 (53.0)	109 (76.2)	93 (65.0)
Fan-shaped shadowing	121 (44.8)	93 (76.9)	71 (58.7)
Junctional-zone abnormality	169 (62.6)	133 (78.7)	108 (63.9)

In this simulated example, direct myometrial features showed stronger patterns with dysmenorrhea, whereas globular uterine morphology, asymmetrical myometrial thickening, and junctional-zone abnormalities showed greater frequencies of HMB. The illustrative findings demonstrate how phenotype-specific analysis can be reported once the actual patient-level data are analyzed.

4. DISCUSSION

The present illustrative analysis suggests that ultrasound-defined adenomyosis phenotypes may be associated with the severity and pattern of menstrual symptoms. In the simulated dataset, dysmenorrhea was present in 72.6% of patients and HMB in 55.9%, highlighting the substantial symptom burden commonly associated with adenomyosis.

Diffuse adenomyosis demonstrated a greater simulated frequency of severe dysmenorrhea (28.9%) than focal adenomyosis (14.4%). Similarly, HMB was more frequent in the diffuse phenotype (62.7%

vs. 45.2%). These patterns are biologically plausible because more extensive myometrial involvement may contribute to altered uterine contractility, inflammation, and disruption of the endometrial–myometrial interface.

Among individual MUSA features, direct findings such as myometrial cysts and hyperechogenic islands showed prominent patterns with dysmenorrhea, whereas globular uterus, asymmetrical myometrial thickening, and junctional-zone abnormalities showed stronger patterns with HMB in the simulated analysis. Published studies have similarly reported associations between individual MUSA features and menstrual symptoms, although the strength and consistency of these relationships vary between populations.

These findings support the clinical value of describing adenomyosis according to standardized ultrasound characteristics rather than reporting the disease merely as present or absent. Identification of symptom-associated phenotypes may potentially improve clinical assessment, patient counselling, and individualized management.

Strengths and Limitations

A major strength of the proposed study is the relatively large sample of 270 patients and the use of standardized MUSA-based ultrasound characterization. However, its retrospective design is an important limitation. Incomplete clinical documentation, absence of standardized VAS/NRS or PBAC measurements in some records, interobserver variability in ultrasound interpretation, and potential confounding by leiomyoma, endometriosis, and hormonal treatment should be considered when interpreting the final results.

5. CONCLUSION

Ultrasound-defined adenomyosis phenotypes appear to show distinct patterns of association with dysmenorrhea and heavy menstrual bleeding. Diffuse disease and a greater sonographic burden may be associated with more severe menstrual symptoms, while individual MUSA features may demonstrate different relationships with pain and bleeding.

Standardized assessment using the revised MUSA

criteria may therefore provide clinically useful information beyond the simple presence or absence of adenomyosis. Incorporating ultrasound phenotype with menstrual symptom assessment could facilitate better clinical characterization, patient counselling, and individualized management. Further prospective studies using standardized pain and menstrual blood-loss measures are required to confirm these phenotype–symptom relationships.

2018;143(3):393-408. doi:10.1002/ijgo.12666.

REFERENCES

1. Abbott JA. Adenomyosis and abnormal uterine bleeding (AUB-A) pathogenesis, diagnosis, and management. *Best Pract Res Clin Obstet Gynaecol.* 2017;40:68-81.
2. Chapron C, Vannuccini S, Santulli P, Abrão MS, Carmona F, Fraser IS, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. *Hum Reprod Update.* 2020;26(3):392-411. doi:10.1093/humupd/dmz049.
3. Dosunmu SD, Sarno A, Lee E, Mitchell C, Wang J, Shaak K. Validation of the revised MUSA criteria for sonographic detection of adenomyosis. *AbdomRadiol (NY).* 2026;51(1):274-282. doi:10.1007/s00261-025-05039-y.
4. Exacoustos C, Manganaro L, Zupi E. Imaging for the evaluation of endometriosis and adenomyosis. *Best Pract Res Clin Obstet Gynaecol.* 2014; 28(5):655-681. doi:10.1016/j.bpobgyn.2014.04.010.
5. Harmsen MJ, Van den Bosch T, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, et al. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure. *Ultrasound Obstet Gynecol.* 2022; 60(1):118-131. doi:10.1002/uog.24786.
6. Kadam N, Khalid S, Jayaprakasan K. How reproducible are the ultrasound features of adenomyosis defined by the revised MUSA consensus? *J Clin Med.* 2025;14(2):456. doi:10.3390/jcm14020456.
7. Kobayashi H, Imanaka S. Understanding ultrasound features that predict symptom severity in patients with adenomyosis: a systematic review. *Reprod Sci.* 2024;31(2):320-331. doi:10.1007/s43032-023-01318-5.
8. Liu L, Li W, Leonardi M, Condous G, Da Silva Costa F, Mol BW, Wong L. Diagnostic accuracy of transvaginal ultrasound and magnetic resonance imaging for adenomyosis: systematic review and meta-analysis and review of sonographic diagnostic criteria. *J Ultrasound Med.* 2021; 40(11):2289-2306. doi:10.1002/jum.15635.
9. Maghsoudlou P, Chatroux LR, Ajao MO, King LP, Groszmann YS. Diagnostic accuracy of ultrasound for adenomyosis a blinded, retrospective, single-expert validation study of the 2022 MUSA guidelines. *J Minim Invasive Gynecol.* 2025;32(11):996-1001.e1. doi:10.1016/j.jmig.2025.07.024.
10. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. *Int J Gynaecol Obstet.*